Year: 2023
Type: article
Abstract: Although nearly a century has elapsed since the discovery of penicillin, bacterial infections remain a major global threat. Global antibiotic use resulted in an astounding 42 billion doses of antibiotics administered in 2015 with 128 billion annual doses expected by 2030. This overuse of antibiotics has led to the selection of multidrug-resistant "super-bugs," resulting in increasing numbers of patients being susceptible to life-threatening infections with few available therapeutic options. New clinical tools are therefore urgently needed to identify bacterial infections and monitor response to antibiotics, thereby limiting overuse of antibiotics and improving overall health. Next-generation molecular imaging affords unique opportunities to target and identify bacterial infections, enabling spatial characterization as well as noninvasive, temporal monitoring of the natural course of the disease and response to therapy. These emerging noninvasive imaging approaches could overcome several limitations of current tools in infectious disease, such as the need for biological samples for testing with their associated sampling bias. Imaging of living bacteria can also reveal basic biological insights about their behavior in vivo.
Language: English
Subfield: Biotechnology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,536
Funders: Burroughs Wellcome Fund, AstraZeneca, GlaxoSmithKline, Johns Hopkins University, Kræftens Bekæmpelse, Neuroendocrine Tumor Research Foundation, Wellcome Trust, Innovationsfonden, Cancer Research UK, National Institute for Health and Care Research, National Research Foundation, Danmarks Grundforskningsfond, Lundbeckfonden, Novo Nordisk, Rigshospitalet, Region Hovedstaden, Novo Nordisk Fonden, H. Lundbeck A/S, National Institutes of Health, University of California, San Francisco, Horizon 2020, NIHR Cambridge Biomedical Research Centre, National Institute of Allergy and Infectious Diseases, National Institute of Biomedical Imaging and Bioengineering, NIH Clinical Center
Awards: Development of 11C-PABA as a bacteria-specific imaging agent for spinal infections, Preclinical modeling to study Tuberculous Meningitis, G2152217899, Next generation tools for imaging bacterial infection and its relationship to the immune system, Clinical translation of D-amino acid derived PET tracers for imaging spinalinfection, G339189699, G3579251033, G3700619227, G3883432169, G4797389680, Sensing living P. aeruginosa using D-alanine derived radiotracers, G581189433, G6753707462, Measuring Intralesional Drug Exposures in Cavitary TB using Noninvasive In Vivo PET Imaging, G8537674695, G9000020876, G996761087
OpenAlex ID: W4387312403